UNSPSC 51342804: Atevirdine mesilate or mesylate

This classification denotes a reverse transcriptase inhibitor with the molecular formula C21H25N5O2.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A948D8673W. The term atevirdine mesilate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule atevirdine mesylate under HS 29335995. As of Q4 2014, ATEVIRDINE MESYLATE remains US FDA's Preferred Term for this commodity. Atevirdine mesylate bears US NLM identifiers UMLS ID C0210242 and NCI Concept Code C73148.

SMILES: CCNC1CCCNC1N2CCN(CC2)C(=O)C3CC4CC(CCC4[NH]3)OC.CS(=O)(=O)O.

UNSPSC 51342804 Atevirdine mesilate or mesylate, a Commodity code, shows limited recent state and local procurement activity directly aligned with its nominal scope. The code's abstract pharmaceutical designation does not reflect the actual purchasing patterns in recent opportunities, which instead focus on naloxone procurement, medical and first aid supplies for emergency response, and multi-source generic pharmaceuticals and OTC products through cooperative purchasing mechanisms. State and local issuing bodies pursuing pharmaceutical and medical-supply contracts include health departments and community health organizations, municipal fire and rescue divisions, and state health and human services agencies participating in multi-state cooperative purchasing alliances. The Seminole County, Florida solicitation (IFB60459723LAS, due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, while the City of Tampa's IFB (26P00145, due March 13, 2026) covers 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000.00 and a 5% small local business enterprise discount available.

Geographic representation spans Florida, Texas, and Minnesota-led multi-state purchasing. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP (S1070000015802, due March 26, 2026) establishes statewide and multi-state contracts for generic multi-source pharmaceuticals and OTC products, with distribution through three authorized wholesalers and product availability required by May 15, 2026. The Texas Health and Human Services Commission RFI (HHS0017013, posted April 3, 2026) solicits vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels, representing a preliminary information-gathering phase before formal competitive solicitation. The code shows minimal activity in its stated commodity scope; firms pursuing pharmaceutical or medical-supply procurement should focus on cooperative purchasing vehicles, state health department contracts, and municipal emergency-response supply chains rather than expect direct opportunities specifically under this code designation.